AU2005311738B2 - Topical nepafenac formulations - Google Patents

Topical nepafenac formulations Download PDF

Info

Publication number
AU2005311738B2
AU2005311738B2 AU2005311738A AU2005311738A AU2005311738B2 AU 2005311738 B2 AU2005311738 B2 AU 2005311738B2 AU 2005311738 A AU2005311738 A AU 2005311738A AU 2005311738 A AU2005311738 A AU 2005311738A AU 2005311738 B2 AU2005311738 B2 AU 2005311738B2
Authority
AU
Australia
Prior art keywords
composition
mannitol
adjusting agent
nepafenac
carbomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005311738A
Other languages
English (en)
Other versions
AU2005311738A1 (en
Inventor
Warren Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35848959&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2005311738(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AU2005311738A1 publication Critical patent/AU2005311738A1/en
Application granted granted Critical
Publication of AU2005311738B2 publication Critical patent/AU2005311738B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2005311738A 2004-12-02 2005-12-02 Topical nepafenac formulations Expired AU2005311738B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63256204P 2004-12-02 2004-12-02
US60/632,562 2004-12-02
PCT/US2005/043545 WO2006060618A2 (en) 2004-12-02 2005-12-02 Topical nepafenac formulations

Publications (2)

Publication Number Publication Date
AU2005311738A1 AU2005311738A1 (en) 2006-06-08
AU2005311738B2 true AU2005311738B2 (en) 2011-02-03

Family

ID=35848959

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005311738A Expired AU2005311738B2 (en) 2004-12-02 2005-12-02 Topical nepafenac formulations

Country Status (23)

Country Link
US (3) US7834059B2 (cg-RX-API-DMAC7.html)
EP (1) EP1819362B1 (cg-RX-API-DMAC7.html)
JP (2) JP4968844B2 (cg-RX-API-DMAC7.html)
KR (1) KR101289661B1 (cg-RX-API-DMAC7.html)
CN (1) CN101068573A (cg-RX-API-DMAC7.html)
AR (1) AR052252A1 (cg-RX-API-DMAC7.html)
AT (1) ATE476200T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005311738B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0518904B1 (cg-RX-API-DMAC7.html)
CA (1) CA2586807C (cg-RX-API-DMAC7.html)
CY (1) CY1110780T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005022756D1 (cg-RX-API-DMAC7.html)
DK (1) DK1819362T3 (cg-RX-API-DMAC7.html)
ES (1) ES2348249T3 (cg-RX-API-DMAC7.html)
MX (1) MX2007006558A (cg-RX-API-DMAC7.html)
PL (1) PL1819362T3 (cg-RX-API-DMAC7.html)
PT (1) PT1819362E (cg-RX-API-DMAC7.html)
RU (1) RU2007124638A (cg-RX-API-DMAC7.html)
SI (1) SI1819362T1 (cg-RX-API-DMAC7.html)
TW (1) TWI358290B (cg-RX-API-DMAC7.html)
UY (1) UY29238A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006060618A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200704763B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
SI1885336T1 (sl) * 2005-05-10 2009-08-31 Alcon Inc Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj
AU2006244245B2 (en) * 2005-05-10 2010-11-18 Alcon, Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
US20080057022A1 (en) * 2006-08-30 2008-03-06 Erning Xia Ophthalmic Pharmaceutical Compositions and Uses Thereof
CN101754748A (zh) * 2007-05-24 2010-06-23 阿西克斯医疗公司 治疗干眼症的制剂和方法
TWI531362B (zh) * 2008-07-21 2016-05-01 艾爾康股份有限公司 具有治療劑遞送能力之眼科裝置
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
US8912236B2 (en) * 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
CN105362221A (zh) * 2009-03-03 2016-03-02 爱尔康研究有限公司 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
HUE038821T2 (hu) 2009-12-03 2018-11-28 Novartis Ag Karboxivinil polimert tartalmazó nanorészecske szuszpenziók
US9544143B2 (en) 2010-03-03 2017-01-10 Duo Security, Inc. System and method of notifying mobile devices to complete transactions
US9532222B2 (en) 2010-03-03 2016-12-27 Duo Security, Inc. System and method of notifying mobile devices to complete transactions after additional agent verification
US9467463B2 (en) 2011-09-02 2016-10-11 Duo Security, Inc. System and method for assessing vulnerability of a mobile device
CN104114154A (zh) * 2011-12-16 2014-10-22 阿勒根公司 包含聚乙烯基己内酰胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物(Soluplus)的眼用组合物
WO2014207769A1 (en) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Process for the preparation of nepafenac
CN104490861A (zh) * 2014-11-21 2015-04-08 三明欣茂药业有限公司 一种缓释型奈帕芬胺眼用制剂
HUE048564T2 (hu) 2015-01-26 2020-08-28 Bausch & Lomb Szemészeti szuszpenzió készítmény
US9930060B2 (en) 2015-06-01 2018-03-27 Duo Security, Inc. Method for enforcing endpoint health standards
CN107024550A (zh) * 2016-12-21 2017-08-08 广州仁恒医药科技股份有限公司 奈帕芬胺眼用药物组合物的质控方法
CN106963730A (zh) * 2016-12-22 2017-07-21 广州仁恒医药科技股份有限公司 高度稳定的奈帕芬胺眼用药物组合物
US10412113B2 (en) 2017-12-08 2019-09-10 Duo Security, Inc. Systems and methods for intelligently configuring computer security
US11658962B2 (en) 2018-12-07 2023-05-23 Cisco Technology, Inc. Systems and methods of push-based verification of a transaction
IT201900000561A1 (it) * 2019-01-14 2020-07-14 Medivis S R L Formulazioni topiche oftalmiche chimicamente e fisicamente stabili a base di Nepafenac
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
CN114272207B (zh) * 2022-01-21 2023-04-11 山东诺明康药物研究院有限公司 一种纳米晶混悬滴眼液及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013805A2 (en) * 2000-08-14 2002-02-21 Alcon, Inc. Method of treating neurodegenerative disorders of the retina and optic nerve head
US20020037929A1 (en) * 2000-08-14 2002-03-28 Alcon Universal Ltd. Method of treating angiogenesis-related disorders
WO2003092669A2 (en) * 2002-05-03 2003-11-13 Alcon, Inc. Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1226344A (cg-RX-API-DMAC7.html) 1967-07-31 1971-03-24
CH577461A5 (cg-RX-API-DMAC7.html) 1975-08-13 1976-07-15 Robins Co Inc A H
US4313949A (en) 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
US4254146A (en) 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en) 1980-02-19 1984-09-30 Robins Co Inc A H 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
US4503073A (en) 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en) 1981-02-17 1982-03-31 Robins Co Inc A H 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
US4568695A (en) 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
US4851443A (en) 1985-03-14 1989-07-25 Smith Kline Dauelsberg, Gmbh Carboxylic acid amides, compositions and medical use thereof
EP0195582B1 (en) 1985-03-14 1990-01-24 SMITH KLINE DAUELSBERG GmbH 5-aminosalicylic acid derivatives of non-steroidal antiinflammatory acids
US4683242A (en) 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
DK406686D0 (da) 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US4910225A (en) 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US5461081A (en) 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5624893A (en) 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
US5475034A (en) 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
WO2004064828A1 (ja) 2003-01-21 2004-08-05 Senju Pharmaceutical Co., Ltd. ２−アミノ−３−(４−ブロモベンゾイル)フェニル酢酸含有水性液剤
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013805A2 (en) * 2000-08-14 2002-02-21 Alcon, Inc. Method of treating neurodegenerative disorders of the retina and optic nerve head
US20020037929A1 (en) * 2000-08-14 2002-03-28 Alcon Universal Ltd. Method of treating angiogenesis-related disorders
WO2003092669A2 (en) * 2002-05-03 2003-11-13 Alcon, Inc. Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac

Also Published As

Publication number Publication date
MX2007006558A (es) 2007-06-15
JP4968844B2 (ja) 2012-07-04
ATE476200T1 (de) 2010-08-15
EP1819362B1 (en) 2010-08-04
CA2586807A1 (en) 2006-06-08
CY1110780T1 (el) 2015-06-10
DE602005022756D1 (de) 2010-09-16
EP1819362A2 (en) 2007-08-22
WO2006060618A3 (en) 2006-10-19
UY29238A1 (es) 2006-05-31
CN101068573A (zh) 2007-11-07
US8324281B2 (en) 2012-12-04
AR052252A1 (es) 2007-03-07
KR20070089687A (ko) 2007-08-31
SI1819362T1 (sl) 2010-10-29
US8071648B2 (en) 2011-12-06
TWI358290B (en) 2012-02-21
JP2012041368A (ja) 2012-03-01
US20120029084A1 (en) 2012-02-02
ES2348249T3 (es) 2010-12-02
PT1819362E (pt) 2010-10-11
TW200626132A (en) 2006-08-01
US7834059B2 (en) 2010-11-16
US20110015271A1 (en) 2011-01-20
BRPI0518904B1 (pt) 2023-01-24
WO2006060618A2 (en) 2006-06-08
HK1104225A1 (en) 2008-01-11
RU2007124638A (ru) 2009-01-10
KR101289661B1 (ko) 2013-07-29
US20060122277A1 (en) 2006-06-08
ZA200704763B (en) 2008-09-25
JP2008521926A (ja) 2008-06-26
DK1819362T3 (da) 2010-10-18
BRPI0518904A2 (pt) 2008-12-16
AU2005311738A1 (en) 2006-06-08
PL1819362T3 (pl) 2010-12-31
CA2586807C (en) 2013-01-29

Similar Documents

Publication Publication Date Title
US8071648B2 (en) Topical nepafenac formulations
JP4968954B2 (ja) 活性成分、ポロキサマー界面活性剤もしくはメロキサポール界面活性剤およびグリコールを含有する懸濁処方物、ならびに眼の障害を処置するための医薬の製造のためのその使用
JP2018030871A (ja) 非刺激性の眼科用ポビドンヨード組成物
JP2011132259A (ja) コンタクトレンズでの使用に適する眼の抗アレルギー組成物
JP3142842B1 (ja) 眼科用組成物及びソフトコンタクトレンズへの吸着抑制方法
EP2734206A1 (en) Fixed dose combination of bimatoprost and brimonidine
JP4968955B2 (ja) 眼用薬物、ポロキサミンおよびグリコール張度調整剤を含有する眼用懸濁液、ならびに眼の障害を処置するための医薬の製造のためのこの組成物の使用
JP2001097865A (ja) 眼科用組成物
JP2002316926A (ja) コンタクトレンズ用眼科用組成物及び眼刺激性の緩和方法
JP2001322936A (ja) 眼科用組成物
WO2007007894A1 (ja) キサンタンガムおよびテルペノイドを含有する点眼剤
JP2003073303A (ja) 眼局所用液剤の清涼化作用の持続方法
JP2009084235A (ja) 眼科用抗充血剤及び抗充血用眼科組成物
HK1104225B (en) Topical nepafenac formulations
JP2007070350A (ja) 眼粘膜適用製剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired